TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00634543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride/ Acetaminophen
Description: Participants will receive 1 tablet containing tramadol HCl 37.5 milligram (mg) and acetaminophen 325 mg once daily, at bed time on Days 1 to 3,. 1 tablet twice daily on Days 4 to 7 and 1 tablet thrice daily on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 8 tablets per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Participants will receive Gabapentin 300 mg once daily at bed time on Day 1, 300 mg twice daily on Day 2 and 300 mg thrice daily on Day 3. Gabapentin 300 mg will be administered twice daily (in the morning and midday) and gabapentin 600 mg in the evening on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 3600 mg per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
Study: NCT03851393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induction of cough with inhaled citric acid
Description: perform artificially induced cough by inhalation of citric acid at various strengths

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peptest™ analysis of saliva pepsin
Description: collect patient saliva for analysis of pepsin levels

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Peptest™
Description: The Peptest™ lateral flow device
Study: NCT03701165

Intervention type: DEVICE
Group type: OTHER
Intervention: DryMouth Shield
Description: The DryMouth Shield provides an elastomeric, one-piece design with breath-actuated, one-way valves configured to create an air-tight seal between the teeth and lips, which effectively reduces oral venting and air leakage while also allowing air flow into the mouth by generating a high-volume, low resistance airflow during inhalation while sealing when the user exhales.
Study: NCT00077623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epoetin alfa or beta
Description: iv 3 times weekly, as prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta (Mircera)
Description: 60, 100 or 180 micrograms sc (starting dose) every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta (Mircera)
Description: 60, 100 or 180 micrograms sc (starting dose) every 4 weeks
Study: NCT03441191

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audiovisual Stimulation
Description: A commercially available AVS device (MindPlace Procyon) modified for use in the current study will be used to deliver the AVS programs in this study

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Audiovisual Stimulation
Description: A commercially available AVS device (MindPlace Procyon) modified for use in the current study will be used to deliver the AVS programs in this study
Study: NCT02286011

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MNC (Mononuclear cells)
Description: The cells are infused into the TA muscle of the lower limb randomized as Group A (experimental) intramuscularly. The infusion is made with a needle, 26 gauge, at 4 points of the TA muscle a specific depth given by the neurophysiological study. The total volume infused will be 2 ml, 0.5 ml at each point.~For infusion is as painless as possible for the patient to comply exactly with stereotactic indications of neurophysiology, the infusion was made at a uniform controlled rate and for this, the syringe is placed on a Yesargil arm, equipped with a microinjector and controlled infusion device.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The placebo, 2ml of saline, will be infused like in the experimental arm.
Study: NCT05468450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided-foam sclerotherapy (UGFS) using Polidocanol sclerosant
Description: Direct injection Foam sclerotherapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous Laser Ablation (EVLA)
Description: EVLA using a 1470nm generator and 600-micron radial fibres (Biolitec® Biomedical Technology, Jena, Germany), under tumescent local anaesthesia (TLA)
Study: NCT03519308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Before Surgery Wks 1 \&3, After Surgery Wks 1 \&3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Before Surgery Wks 1 \&3, After Surgery Wks 1 \&3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Wks 1,2,3 before surgery and Wks 1, 2,3 after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Wks 1,2,3 before surgery and Wks 1, 2,3 after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Wks 1,2,3 before surgery and Wks 1,2,3 after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Wks 1,2,3 before surgery and Wks 1,2,3 after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Wks 1,2,3, 4 before surgery and Wks 1,2,3 after surgery
Study: NCT01531218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin
Description: azithromycin, oral use, 500mg per day for 3 days in total. Total dose 1500mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04367337

Intervention type: OTHER
Intervention: No intervention
Description: Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country

Intervention type: OTHER
Intervention: No intervention
Description: Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country

Intervention type: OTHER
Intervention: No intervention
Description: Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country

Intervention type: OTHER
Intervention: No intervention
Description: Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country

Intervention type: OTHER
Intervention: No intervention
Description: Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country

Intervention type: OTHER
Intervention: No intervention
Description: Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country

Intervention type: OTHER
Intervention: No intervention
Description: Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country

Intervention type: OTHER
Intervention: No intervention
Description: Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country

Intervention type: OTHER
Intervention: No intervention
Description: Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country

Intervention type: OTHER
Intervention: No intervention
Description: Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country

Intervention type: OTHER
Intervention: No intervention
Description: Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country

Intervention type: OTHER
Intervention: No intervention
Description: Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country

Intervention type: OTHER
Intervention: No intervention
Description: Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country

Intervention type: OTHER
Intervention: No intervention
Description: Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
Study: NCT04134104

Intervention type: PROCEDURE
Intervention: Surgery for Colorectal malignant diseases either LAR or APR
Description: Patients following LAR or APR were observed for the Bowel, Bladder, and Sexual Dysfunction
Study: NCT03400670

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ventilator NCPAP
Description: infants will be randomized into two different NCPAP groups

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ventilator NCPAP
Description: infants will be randomized into two different NCPAP groups
Study: NCT03717324

Intervention type: OTHER
Intervention: Procedure created in co-creation group
Description: Interventions will be those obtained from the co-creation workshop with patients

Intervention type: OTHER
Intervention: Procedure created in co-creation group
Description: Interventions will be those obtained from the co-creation workshop with patients
Study: NCT00581711

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3-Part Intervention
Description: A combination of training, an otitis media episode grouper, and clinical decision support.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4-Part Intervention
Description: A combination of clinician training, an otitis media episode grouper, clinical decision support, and feedback.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1-part intervention
Description: Provision of feedback on otitis media quality indicators
Study: NCT01275261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing protocol to avoid Foley catheter placement
Description: A specific nursing order protocol will be followed addressing urinary care to try to avoid the use of Foley catheters.
Study: NCT03851679

Intervention type: DIAGNOSTIC_TEST
Intervention: B-Type natriuretic peptide (BNP) serum values
Description: evaluation BNP serum values:~* pre- Cesarean Section (30 minutes before surgery)~* post- Cesarean Section (6 hour and 24 hour after surgery)

Intervention type: DEVICE
Intervention: Pulmonary echography
Description: Pulmonary echography:~* pre- Cesarean Section (30 minutes before surgery)~* post- Cesarean Section (6 hour and 24 hour after surgery)

Intervention type: OTHER
Intervention: urine collection
Description: 6 hour and 24 hour urine collection after Cesarean Section
Study: NCT02401256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements.
Study: NCT00292292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumbar Artificial Disc
Description: Insertion of the Kineflex Lumbar ArtificialDisc

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Charite Artificial Disc
Description: Insertion of the Charite
Study: NCT01382589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide
Description: NB-UVB phototherapy with or without subcutaneous, bioresorbable Afamelanotide 16 mg implants, contained in a poly(D,L-lactide-co-glycolide) implant core released over 7-10 days following implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NB-UVB
Description: NB-UVB light therapy 3-times per week, for total of 72 treatments
Study: NCT01264991

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy
Description: The arthroscopic partial meniscectomy will be performed on an outpatient basis by experienced surgeons at a level of at least attending physicians or at the last year of residency. All arthroscopies will be performed in general anaesthesia combined with local anaesthesia. After general anaesthesia is induced, the knee will be examined for stability. Thereafter two standard portals on the lateral and medial side of the ligamentum patella will be created but no outflow cannula inserted. An arthroscope will be used with a pressure-controlled irrigation system. Tourniquet use will be according to surgeon preference. The strategy for the meniscectomy will be to preserve as much tissue as possible. A standard operation protocol will be used to document possible findings in cartilage, ligaments, synovium and the medial and lateral meniscus. Meniscus lesions and type of will be registered and changes in the articular cartilage will be classified according to the ICRS classification

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham procedure
Description: The placebo procedure will be performed under the same conditions as above. The patient will be fully sedated in general anaesthesia. As above, the stability of the knee will be examined. Local anaesthetic will be applied as above and 2 skin incisions will be made at the same location and the same size as above. Then the knee will be manipulated as if a real arthroscopy were being done, the spillage of water and all the other equipment needed for an arthroscopy will be used and manipulated. No instruments will enter the portals for arthroscopy to avoid the possibility of osteochondral lesions and unwanted interventions by the surgeon.
Study: NCT04384640

Intervention type: OTHER
Intervention: Change of posture after Intra Tympanic injection
Description: Seating position after Intra Tympanic injection
Study: NCT00069095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 130 mg/m^2
Description: Oxaliplatin was administered in a 2 h infusion before the first dose of capecitabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 130 mg/m^2
Description: Oxaliplatin was administered in a 2 h infusion before the first dose of capecitabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine 1000 mg/m^2
Description: Capecitabine was taken within 30 min after the end of breakfast and dinner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine 1000 mg/m^2
Description: Capecitabine was taken within 30 min after the end of breakfast and dinner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab 7.5 mg/kg
Description: Bevacizumab was administered in a 30 to 90 min infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for bevacizumab 7.5 mg/kg
Description: Placebo control for bevacizumab (volume equivalent to 7.5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin 85 mg/m^2
Description: Oxaliplatin 85 mg/m\^2 was administered simultaneously with leucovorin in a 2 h infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin 85 mg/m^2
Description: Oxaliplatin 85 mg/m\^2 was administered simultaneously with leucovorin in a 2 h infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin 200 mg/m^2
Description: Leucovorin was administered simultaneously with oxaliplatin 85 mg/m\^2 in a 2 h infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin 200 mg/m^2
Description: Leucovorin was administered simultaneously with oxaliplatin 85 mg/m\^2 in a 2 h infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil 400 mg/m^2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil 400 mg/m^2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab 5 mg/kg
Description: Bevacizumab was administered in a 30 to 90 min infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for bevacizumab 5 mg/kg
Description: Placebo control for bevacizumab (volume equivalent to 5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.
Study: NCT03073070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biotin labeled RBCs
Description: Autologous red blood cells are biotin labeled and transfused to the subjects. Survival of these red blood cells is tracked through examination of blood samples until no biotin-labeled red blood cells is detectable.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biotin labeled RBCs
Description: Autologous red blood cells are biotin labeled and transfused to the subjects. Survival of these red blood cells is tracked through examination of blood samples until no biotin-labeled red blood cells is detectable.
Study: NCT03988777

Intervention type: DEVICE
Intervention: Preoperative localisation technique
Description: Impalpable breast lesions are preoperatively localised, either with hooked-wire (retrospective study) or Magseed (prospective study)

Intervention type: DEVICE
Intervention: Preoperative localisation technique
Description: Impalpable breast lesions are preoperatively localised, either with hooked-wire (retrospective study) or Magseed (prospective study)
Study: NCT02222987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbogrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Study: NCT02645448

Intervention type: OTHER
Group type: OTHER
Intervention: Resistance Exercise
Description: Control Session~Resistance exercise at different intensities (40%1RM or 80%1RM)~Duration of effect

Intervention type: OTHER
Group type: OTHER
Intervention: Resistance Exercise
Description: Control Session~Resistance exercise at different intensities (40%1RM or 80%1RM)~Duration of effect
Study: NCT02093585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abacavir (600 mg QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir (245 mg QD)
Study: NCT04042662

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT03491163

Intervention type: DIAGNOSTIC_TEST
Intervention: Syndecan-1 concentration evaluation
Description: Blood sample will be taken and analysed using ELISA method.
Study: NCT01165203

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster Vaccine GSK1437173A
Description: intramuscular injection
Study: NCT06671899

Intervention type: OTHER
Intervention: Constraint-induced movement therapy (CIMT)
Description: Clinically implemented modified CIMT. Including the three main components; intensive and repetitive task-oriented training of the affected limb, constraint of the non-affected limb and behavioural strategies known as the Transfer Package. In this model the training is supervised by therapist from several professions and some training sessions is performed in group settings with other inpatients and outpatients undergoing primary rehabilitation at the clinic.
Study: NCT02461511

Intervention type: OTHER
Intervention: Therapeutic Education
Description: participation in a therapeutic education program on diabetes
Study: NCT02062411

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT only
Description: Participants will learn 12 sessions including educational information about ADHD and skills in organization and plan, reducing distractibility, and adaptive thinking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT with booster sessions
Description: Participants are provided with the same CBT programme and additional 3 booster sessions which summarize and extend the 3 main topics of the CBT programme in order to improve the skills practice ability.
Study: NCT04196296

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Online psychoeducation about social anxiety, evidence-based treatments that target social anxiety, and treatment referral/resource information.
Study: NCT01367587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Methylnaltrexone
Study: NCT01165203

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intramuscular injection
Study: NCT01509586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potentially Reduced Exposure Product (PREP): a smokeless, spit-free tobacco product
Description: The PREP Group will be given a sample supply of a PREP product that is already on the market. It is unclear if it is safer than cigarettes, and that is why it is classified as a Potentially Reduced Exposure Product. It provides both nicotine and tobacco in the form of a pouch that can be thrown away after used. Unlike chewing tobacco, there is no need for spitting with this product. There are multiple flavors and participants will have his/her choice of preferred flavor. This group will be asked to sample the product and use it in several ways, but whether a participant uses the product or not is up him/her.